既往放疗后寡复发前列腺癌采用无缝照射野衔接的择区淋巴结放疗
该研究评估既往放疗后淋巴结复发患者接受择区淋巴结放疗(ENRT)时采用无缝照射野衔接方案的可行性。22例PSMA-PET/CT分期淋巴结寡复发患者接受盆腔(14例)或腹主动脉旁(9例)ENRT,1例序贯两部位。计划约束Dmax-cum≤95 Gy和D1cc-cum<90 Gy分别23/23和22/23例达到,中位随访33.5个月,无超过基线的≥3级急慢性毒性。
要点
- 22例既往放疗后淋巴结寡复发前列腺癌患者接受盆腔或腹主动脉旁ENRT,采用无缝照射野衔接。
- Dmax-cum≤95 Gy约束23/23例达到,D1cc-cum<90 Gy约束22/23例达到。
- 中位随访33.5个月,无超过基线的≥3级急性或晚期毒性。
核心结论
- 既往放疗后淋巴结复发患者采用无缝照射野衔接的ENRT似乎是可行的,应用Dmax-cum≤95 Gy和D1cc-cum<90 Gy剂量约束,无超过基线的3级急性或晚期毒性。
研究设计与样本
- 分析既往前列腺或前列腺窝放疗后接受盆腔ENRT、或既往盆腔放疗后接受腹主动脉旁淋巴结ENRT且照射野无缝衔接的患者,共22例。
主要发现
- 22例PSMA-PET/CT分期淋巴结寡复发患者接受盆腔ENRT 14例或腹主动脉旁ENRT 9例,1例序贯两部位。
- 首次与第二次放疗中位时间20.2个月,淋巴引流途径中位剂量47.5 Gy,PET阳性淋巴结中位剂量64.8 Gy。
- Dmax-cum≤95 Gy约束23/23例达到,D1cc-cum<90 Gy约束22/23例达到。
- 中位随访33.5个月,无超过基线的≥3级急性或晚期毒性。
- 超过基线的最重急性毒性为1级68.2%、2级22.7%;最重晚期毒性为1级31.8%、2级18.2%。
关键数值与推荐
- 计划约束:估计Dmax-cum≤95 Gy,D1cc-cum<90 Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the feasibility of subsequent elective nodal radiotherapy (ENRT) for nodal recurrences after previous radiotherapy with a defined planning approach for a gapless radiation field junction. METHODS: Patients with 1) previous radiotherapy of prostate or prostatic fossa and subsequent pelvic ENRT or 2) previous pelvic radiotherapy and subsequent ENRT to paraaortic lymph nodes (LN) and gapless junction of both radiation fields were analyzed. The cumulative maximum dose (Dmax-cum) and the maximum cumulative dose in 1 cc (D1cc-cum) were estimated. Absolute toxicity and the toxicity exceeding baseline were evaluated. RESULTS: Twenty-two patients with PSMA-PET/CT-staged nodal oligorecurrence after prior radiotherapy were treated with pelvic (14 patients) or paraaortic ENRT (9 patients). One patient was treated sequentially at both locations. Median time between first and second RT was 20.2 months. Median doses to the lymphatic pathways and to PET-positive LN were 47.5 Gy and 64.8 Gy, respectively. The planning constraint of an estimated Dmax-cum ≤ 95 Gy and of D1cc-cum < 90 Gy were achieved in 23/23 cases and 22/23 cases, respectively. Median follow-up was 33.5 months. There was no additional acute or late toxicity ≥ grade 3. Worst acute toxicity exceeding baseline was grade 1 in 68.2% and grade 2 in 22.7% of patients. Worst late toxicity exceeding baseline was grade 1 in 31.8% and grade 2 in 18.2% of patients. CONCLUSION: ENRT for nodal recurrences after a previous radiotherapy with gapless junction of radiation fields seems to be feasible, applying the dose constraints Dmax-cum ≤ 95 Gy and D1cc-cum < 90 Gy without grade 3 acute or late toxicities exceeding baseline.
引用
- Li M, Fan Y, Trapp C, et al. Elective nodal radiotherapy with a gapless radiation field junction for oligorecurrent prostate cancer after previous radiotherapy. Clin Transl Radiat Oncol. 2022. PMID: 36605290. doi:10.1016/j.ctro.2022.100571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。